224 related articles for article (PubMed ID: 24195728)
1. Emerging drugs for urothelial carcinoma.
Gartrell BA; Sonpavde G
Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
Vaughn DJ
Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
[TBL] [Abstract][Full Text] [Related]
4. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
Sternberg CN; Bellmunt J; Sonpavde G; Siefker-Radtke AO; Stadler WM; Bajorin DF; Dreicer R; George DJ; Milowsky MI; Theodorescu D; Vaughn DJ; Galsky MD; Soloway MS; Quinn DI;
Eur Urol; 2013 Jan; 63(1):58-66. PubMed ID: 22917984
[TBL] [Abstract][Full Text] [Related]
5. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Tsai YS; Tzai TS; Chow NH
Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy for urothelial cancer of the bladder--update 2012].
Niegisch G; Lorch A; Albers P
Aktuelle Urol; 2012 Dec; 43(6):412-9. PubMed ID: 23196781
[TBL] [Abstract][Full Text] [Related]
7. Novel molecular targets for the therapy of urothelial carcinoma.
Jana BR; Galsky MD; Hahn NM; Milowsky MI; Sonpavde G
Expert Opin Ther Targets; 2012 May; 16(5):499-513. PubMed ID: 22510032
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?
Balar AV; Milowsky MI
Cancer; 2015 Jan; 121(2):179-87. PubMed ID: 25091501
[TBL] [Abstract][Full Text] [Related]
9. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
Ortmann CA; Mazhar D
Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
11. Systemic chemotherapy for advanced bladder cancer: update and controversies.
Garcia JA; Dreicer R
J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
[TBL] [Abstract][Full Text] [Related]
12. A plea for uniform terminology for patients with urothelial carcinoma treated with chemotherapy prior to radical cystectomy: induction versus neoadjuvant chemotherapy.
Liedberg F; Gudjonsson S; Kollberg P; Ullén A
Eur Urol; 2015 Oct; 68(4):742-3. PubMed ID: 26047581
[No Abstract] [Full Text] [Related]
13. Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
Palacka P; Slopovsky J; Obertova J; Chovanec M; Rejlekova K; Sycova-Mila Z; Kollarik B; Mardiak J; Mego M
Anticancer Res; 2021 Nov; 41(11):5749-5759. PubMed ID: 34732448
[TBL] [Abstract][Full Text] [Related]
14. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.
Huang SY; Wu CC; Hsieh MC; Rau KM; Chiang PH; Sung MT; Luo HL; Huang CC; Huang CH; Liu JM; Su HY
Oncology; 2020; 98(3):146-153. PubMed ID: 31794969
[TBL] [Abstract][Full Text] [Related]
15. Value of current chemotherapy and surgery in advanced and metastatic bladder cancer.
Racioppi M; D'Agostino D; Totaro A; Pinto F; Sacco E; D'Addessi A; Marangi F; Palermo G; Bassi PF
Urol Int; 2012; 88(3):249-58. PubMed ID: 22354060
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment of metastatic disease: cisplatin-ineligible patients.
Cathomas R; De Santis M; Galsky MD
Hematol Oncol Clin North Am; 2015 Apr; 29(2):329-40, x. PubMed ID: 25836938
[TBL] [Abstract][Full Text] [Related]
17. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
Gallagher DJ; Milowsky MI; Bajorin DF
Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
[TBL] [Abstract][Full Text] [Related]
18. Future directions and targeted therapies in bladder cancer.
Sonpavde G; Jones BS; Bellmunt J; Choueiri TK; Sternberg CN
Hematol Oncol Clin North Am; 2015 Apr; 29(2):361-76, x. PubMed ID: 25836940
[TBL] [Abstract][Full Text] [Related]
19. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
Fleischmann A; Thalmann GN; Perren A; Seiler R
Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
[TBL] [Abstract][Full Text] [Related]
20. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]